The primary role of Gerdilium (domperidone) is to provide symptomatic relief across therapeutic domains associated with impaired upper gastrointestinal function and the sensation of sickness. As an anti-sickness medicine, it may assist with easing the distressing symptoms of feeling or being sick (nausea or vomiting).

The medication is commonly used across conditions presenting with recurrent or episodic manifestations, such as functional dyspepsia and symptoms related to gastroparesis (slowed stomach emptying). It plays a role in managing symptom clusters of epigastric fullness, bloating, and early satiety, while also being applied in addressing peripheral gastrointestinal side effects, such as nausea, caused by essential primary drug regimens.

“It provides support that helps ease the overall symptom burden,” contributing to improved comfort during periods of heightened symptoms. This medicine is relevant when short-term symptomatic assistance is needed during acute episodes or when supportive symptom management is appropriate for chronic conditions.

---

Quick Fact: Relief for Upper GI Discomfort

---

Eligibility and Contraindications

Gerdilium (domperidone) is approved for use in adults and adolescents who are 12 years of age or older and weigh 35 kg or more. Its use is not recommended in children under 12 years of age or those weighing less than 35 kg, as efficacy has not been established in this group.

The medicine is contraindicated and must not be used in several populations. These include patients with underlying cardiac diseases such as congestive heart failure, known QTc prolongation, or significant electrolyte disturbances. Use is also prohibited in patients with moderate or severe hepatic impairment, a prolactin-releasing pituitary tumour, or conditions where stimulating gut movement could be harmful, such as gastrointestinal haemorrhage or perforation.

Population-Specific Restrictions

Special caution is required for individuals over 60 years of age due to a documented higher risk of serious cardiac events. Patients with severe renal impairment require a reduction in dosing frequency. During lactation, the drug is excreted in human milk, and caution is required due to the potential for adverse effects in the infant.

Gerdilium (domperidone) has several documented interaction patterns that are classified by regulatory authorities based on their potential to alter drug exposure or compound safety risks.

A key restriction is the contraindication of co-administration with two main categories of substances. First, co-administration with potent CYP3A4 inhibitors is strictly prohibited. This is because domperidone is primarily metabolized by the CYP3A4 enzyme, and its inhibition significantly raises domperidone's plasma concentration. Examples of potent inhibitors listed in regulatory labels include certain azole antifungals and macrolide antibiotics, as well as common substances like grapefruit juice. Second, co-administration is also contraindicated with any QTc-prolonging medicinal product (such as specific anti-arrhythmics or antipsychotics) due to an official risk of additive pharmacodynamic effects that can lead to QTc interval prolongation.

Other interactions require careful administration management. Substances that reduce gastric acidity, such as antacids and antisecretory agents, are officially documented to decrease the oral bioavailability of domperidone. Consequently, these agents must not be taken at the same time and require a mandatory timing separation. Furthermore, domperidone's use is formally contraindicated in patients with moderate or severe hepatic impairment, as regulatory data confirms a significantly higher exposure in this population.

Gerdilium's mechanism of action relies on the targeted and highly selective antagonism (blockade) of dopamine D2 and D3 receptors in the body's periphery. This dual action modulates two distinct physiological systems, which together produce the drug's overall physiological effect.

Modulation of Neurotransmitter Signaling in the CTZ

This domain focuses on the antagonistic interaction with D2/ D3 receptors located within the Chemoreceptor Trigger Zone (CTZ). Because the CTZ is functionally outside the main blood-brain barrier, the peripherally selective drug can access it. By blocking the pro-emetic dopamine signaling in this critical area, the mechanism suppresses the afferent signals that would otherwise activate the brain's vomiting center, leading to functional suppression of the vomiting reflex pathway.

Physiological Consequence: Upper Gastrointestinal Motility

This second domain involves the drug's action on D2/ D3 receptors within the enteric nervous system—the intrinsic neural network controlling the gut. Blocking these inhibitory receptors removes the dopamine-mediated 'brake' on the movement of the stomach and duodenum, resulting in an increase in acetylcholine release. This modification of the autonomic pathway results in enhanced smooth muscle contractions and modulated coordination, which results in an acceleration of gastric emptying.

Official Administration Guidelines for Gerdilium (Domperidone)

This section outlines the standardized usage instructions for Gerdilium.

Instruction	Guideline
Route of Administration	Primarily Oral (tablet, suspension, orodispersible tablet). Rectal (suppository) is an alternative route in some regions.
Standard Dosing Schedule	Adults and Adolescents (ge 12 years and ge 35 kg): 10 mg per dose, taken up to three times daily. The Maximum Daily Dose must not exceed 30 mg.
Timing in Relation to Meals	Must be taken before meals (e.g., 15 to 30 minutes prior to eating). Taking the dose after meals may slightly delay its absorption.
Frequency and Interval	Doses should be spaced by approximately 8 hours and taken a maximum of three times per day.
Treatment Duration	The maximum duration of treatment usually should not exceed one week (7 days) for acute symptoms.
Special Population Rule	For patients with severe renal impairment, the official dosing frequency must be reduced to once or twice daily due to prolonged drug elimination.
Missed Dose Protocol	If a scheduled dose is missed, it must be omitted, and the regular dosing schedule should be resumed with the next dose; the dose should not be doubled to compensate.

---

Procedural Structure

Official instructions establish a strict, time-dependent protocol for using this medicine. The 10 mg dose is taken orally, ideally before a meal, and the administration frequency is limited to three times per day. The entire course of treatment is procedurally constrained by the maximum 7-day duration to limit total exposure. The required reduction in dosing frequency for severe kidney impairment is a standard adjustment to the regimen.

Research Evidence / Overview of Studies for Gerdilium

Evidence for Use in Acute Nausea and Vomiting

Gerdilium was studied for its use in examining outcomes related to sudden, acute nausea and vomiting, which are conditions characterized by disruptive or acute episodes. Research exploring this was primarily conducted using short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies examined patient-reported experiences by measuring specific symptomatic changes, such as the frequency of vomiting episodes and the intensity of nausea severity scores over brief observation periods.

Findings describe patterns observed in the studies with acute symptoms. Research highlights changes measured during the study period, which contribute to understanding how the acute symptoms evolved in the observed populations relative to comparison groups. However, the nature of these studies means that follow-up durations were limited, and long-term effects are not fully established regarding the repeated use or maintenance of effects if episodes return.

---

Evidence for Use in Functional Dyspepsia

Research has explored Gerdilium for its application in conditions marked by functional limitations, specifically functional dyspepsia, which involves symptoms such as fullness, bloating, and early satiety. Studies exploring this included intermediate-term RCTs and observational settings. Research monitored outcomes related to physical discomfort, using Global Symptom Severity Scores and examining patient-reported outcomes such as the intensity of bloating. Findings indicate patterns related to reported changes in these symptoms over the defined time intervals.

Key research limitation frames noted include that evidence is limited regarding the durability of these effects, and findings were mixed, meaning subgroup findings are uncertain. Evidence quality varies across studies, and there is also limited information for long-term outcomes related to sustained control of these chronic symptoms.

---

What Is Still Uncertain About Gerdilium Research

The evidence base for Gerdilium has documented uncertainties and limitations. Key research limitation frames include that sample sizes were modest in specialized populations (such as gastroparesis studies), and comparative evidence is lacking when assessing the medicine against other potential therapies. Furthermore, certainty remains low regarding sustained, long-term outcomes, and research is ongoing to address these gaps.

Key Studies & References

1. Clinical Guideline: Management of acute gastroenteritis and persistent vomiting in children

Common questions about Gerdilium (FAQ)

Q: What is Gerdilium used to treat?

A: Gerdilium is officially indicated for the relief of symptoms associated with gastroesophageal reflux (GERD) and heartburn. Regulatory documents describe the intended action as neutralizing stomach acid and forming a protective layer over the stomach contents. This official mechanism is designed to reduce the discomfort and irritation caused by acid rising into the esophagus.

Q: Does Gerdilium contain aluminum or magnesium?

A: Regulatory documents state that Gerdilium contains both aluminum hydroxide and magnesium carbonate as active substances. These compounds function as antacids that provide relief from acidity. These two antacids are often combined in regulatory formulations.

Q: Is Gerdilium suitable for use during pregnancy or while breastfeeding?

A: Official information indicates that the use of Gerdilium during pregnancy and breastfeeding should only occur after careful consideration of the risks and benefits by a healthcare professional. While some regulatory documents suggest limited systemic absorption, consultation with a doctor or pharmacist is a necessary step. A consultation is required because the decision must take into account the individual benefits and potential risks.

Q: Are there specific conditions or health issues that prevent me from taking Gerdilium?

A: According to the official product information, Gerdilium is contraindicated, meaning it should not be used, in people with known hypersensitivity to the active substances or excipients (other ingredients). Studies and official information also advise against its use in patients with severe renal impairment due to the content of aluminum and magnesium. Regulatory information advises against its use in people with significant kidney problems, as this condition is a listed contraindication.

Q: Should Gerdilium be taken with or without food?

A: Regulatory documents state that Gerdilium should be taken one hour after main meals and before bedtime. Following the official recommendation for timing is crucial for its use in treating reflux symptoms. This dosing schedule, taken after meals and at bedtime, is specified in the official guidance to address the timing of symptoms.

Official Storage and Disposal Instructions

Gerdilium must be stored strictly according to the conditions defined in its official regulatory labeling to ensure stability and safety.

Storage Requirement	Official Regulatory Statement
Temperature	Store below 30 C (86 F). Do not refrigerate or freeze.
Environmental Protection	Protect from light and moisture.
Container	Store in the original package. Keep containers tightly closed.
Child Protection	Keep out of the sight and reach of children. Store locked up.

Expired or unused Gerdilium must be handled as pharmaceutical waste. Dispose of the product in accordance with local, regional, and national regulations, and do not dispose of medicines via wastewater or household waste. The product remains stable until its labeled expiry date when these conditions are met.